Vaxcyte, Inc. (PCVX)
Nasdaq · Healthcare · Biotechnology
$73.82+30.70%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $11.0B
- 52-week range
- $39.87 – $90.75
- 52-week change
- +37.05%
- EPS (trailing)
- −$7.62
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Net income
- −$767K
- Diluted EPS
- −$5.63
- Free cash flow
- −$669M
From the company’s annual report on SEC EDGAR.
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Headquarters: San Carlos, United States · 507 employees · vaxcyte.com